# Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
Canonical URL: https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may
Ticker: FHTX
Company: Foghorn Therapeutics
Source: Foghorn Therapeutics
Published: 2026-05-12 11:00 EST
Original Source URL: https://ir.foghorntx.com
## Summary

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C.

## Article Body
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C.
## Recent Company News
- 2026-05-12 11:00 EST — [Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may) — Source: Foghorn Therapeutics
- 2026-05-07 11:00 EST — [Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update) — Source: Foghorn Therapeutics
- 2026-04-21 20:05 EST — [Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting) — Source: Foghorn Therapeutics
- 2026-04-09 11:00 EST — [Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting) — Source: Foghorn Therapeutics
- 2026-03-11 20:10 EST — [Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-financial-update-for-2025-and-2026-strategic-outlook) — Source: Foghorn Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)